Anhui Anke Biotechnology Group Co Ltd
SZSE:300009

Watchlist Manager
Anhui Anke Biotechnology Group Co Ltd Logo
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Watchlist
Price: 8.83 CNY -1.23%
Market Cap: 14.8B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+39%
Revenue
Forecast
+8%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
Anhui Anke Biotechnology Group Co Ltd

Wall Street analysts forecast Anhui Anke Biotechnology Group Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Anhui Anke Biotechnology Group Co Ltd is 11 CNY with a low forecast of 10.89 CNY and a high forecast of 11.32 CNY.

Lowest Forecast
Wall Street Target
10.89 CNY
23% Upside
Average Forecast
Wall Street Target
11 CNY
25% Upside
Highest Forecast
Wall Street Target
11.32 CNY
28% Upside
Lowest
Price Target
10.89 CNY
23% Upside
Average
Price Target
11 CNY
25% Upside
Highest
Price Target
11.32 CNY
28% Upside
Anhui Anke Biotechnology Group Co Ltd Competitors:
Price Targets
CUV
Clinuvel Pharmaceuticals Ltd
123% Upside
1530
3SBio Inc
17% Downside
AZT
Arcticzymes Technologies ASA
6% Upside
EXEL
Exelixis Inc
2% Upside
CUV
Clinuvel Pharmaceuticals Ltd
123% Upside
1530
3SBio Inc
17% Downside
AZT
Arcticzymes Technologies ASA
6% Upside
EXEL
Exelixis Inc
2% Upside
9926
Akeso Inc
15% Upside
688363
Bloomage Biotechnology Corp Ltd
5% Upside
SKYE
Skye Bioscience Inc
871% Upside
B
377740
BioNote Inc
19% Upside

Revenue
Forecast

Revenue Estimate
Anhui Anke Biotechnology Group Co Ltd

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's revenue is 21%. The projected CAGR for the next 3 years is 13%.

21%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Anhui Anke Biotechnology Group Co Ltd

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's operating income is 26%. The projected CAGR for the next 3 years is 13%.

26%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Anhui Anke Biotechnology Group Co Ltd

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's net income is 26%. The projected CAGR for the next 3 years is 14%.

26%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Anhui Anke Biotechnology Group Co Ltd's stock price target?
Price Target
11 CNY

According to Wall Street analysts, the average 1-year price target for Anhui Anke Biotechnology Group Co Ltd is 11 CNY with a low forecast of 10.89 CNY and a high forecast of 11.32 CNY.

What is Anhui Anke Biotechnology Group Co Ltd's Revenue forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's revenue is 21%. The projected CAGR for the next 3 years is 13%.

What is Anhui Anke Biotechnology Group Co Ltd's Operating Income forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's operating income is 26%. The projected CAGR for the next 3 years is 13%.

What is Anhui Anke Biotechnology Group Co Ltd's Net Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's net income is 26%. The projected CAGR for the next 3 years is 14%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 240,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.